Abstract | PURPOSE: METHODS: AOST1421 was a single-arm Phase 2 study for patients with recurrent pulmonary osteosarcoma in complete surgical remission. Patients received up to five cycles of dinutuximab (70 mg/m2/cycle) with granulocyte-macrophage colony-stimulating factor ( GM-CSF). Two different dinutuximab infusion schedules were studied: 35 mg/m2/day over 20 h (2 days) and 17.5 mg/m2/day over 10 h (4 days). Primary end point was DCR, defined as a proportion of patients event free at 12 months from enrolment. The historical benchmark was 12-month DCR of 20% (95% CI 10-34%). Dinutuximab would be considered effective if ≥ 16/39 patients remained event free. Secondary objectives included toxicity evaluation and pharmacokinetics. RESULTS: Thirty-nine eligible patients were included in the outcome analysis. Dinutuximab did not demonstrate evidence of efficacy as 11/39 patients remained event free for a DCR of 28.2% (95% CI 15-44.9%). One of 136 administered therapy cycles met criteria for unacceptable toxicity when a patient experienced sudden death of unknown cause. Other ≥ Grade 3 toxicities included pain, diarrhoea, hypoxia, and hypotension. Pharmacokinetic parameters were similar in the two schedules. CONCLUSIONS:
|
Authors | Pooja Hingorani, Mark Krailo, Allen Buxton, Paul Hutson, Paul M Sondel, Mitchell Diccianni, Alice Yu, Carol D Morris, Richard B Womer, Brian Crompton, R Lor Randall, Lisa A Teot, Steven G DuBois, Katherine A Janeway, Richard G Gorlick, Michael S Isakoff |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 172
Pg. 264-275
(Sep 2022)
ISSN: 1879-0852 [Electronic] England |
PMID | 35809374
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2022 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- dinutuximab
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- Adolescent
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
(toxicity)
- Bone Neoplasms
(drug therapy)
- Child
- Granulocyte-Macrophage Colony-Stimulating Factor
(therapeutic use)
- Humans
- Neoplasm Recurrence, Local
(drug therapy)
- Osteosarcoma
(drug therapy)
- Young Adult
|